SEP 24, 2018 09:01 PM PDT

Further Challenges in Alzheimer Drug Development

WRITTEN BY: Nouran Amin

Image via stress.com

Scientists at Trinity College Dublin performed a large-scale international study involving the treatment of Alzheimer's disease, which was published in PLOS Medicine. The research involved a clinical trial testing a new treatment against a placebo. The study involved a clinical trial, known as NILVAD, which tested 511 participants with mild to moderate Alzheimer’s disease. The clinical trial was testing a new treatment, a medication called Nilvadipine, against a placebo.

The drug, Nilvadipine, is approved to treat high blood pressure. However, in animal studies, it was found to reduce brain amyloid, the toxic protein associated with Alzheimer's disease. Thus, Nilvadipine was seen as a potential treatment for Alzheimer’s. It was therefore considered to be a possible effective treatment for Alzheimer's disease in patients.

The most common form of dementia, Alzheimer's disease affects approximately 34 million people worldwide and as of now, there is no treatment that can delay the onset or slow the progression of the disease.

Results of the study showed that although Nilvadipine is tolerable in individuals with Alzheimer's disease. No effects on memory and function were evident from the drug treatment. "The outcome of the trial for the overall combined group of people with mild and moderate Alzheimer's disease was negative; however, when we broke it down according to severity, those with mild disease appeared to benefit from Nilvadipine whereas those with moderate disease seemed to do worse on the medication. These findings will need to be followed up and teased apart in future studies. It may be that to be successful, we would need to target people at the earliest phase of the disease process,” explains lead author of the study, Professor of Brian Lawlor.

Findings from the paper further implicate drug development for Alzheimer’s.

Source: PLOS Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 11, 2018
Drug Discovery
SEP 11, 2018
Potential Non-Antibiotic Drug For Tuberculosis
After 10 years of research, scientists at the University of Manchester have created the first non-antibiotic drug that can successfully treat tuberculosis ...
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Treating Restless Leg Syndrome (RLS)
A common condition of the nervous system, Restless Leg Syndrome (RLS) is the overwhelming urge to move the legs. Usually unpleasant symptoms, many RLS pati...
NOV 25, 2018
Drug Discovery
NOV 25, 2018
Advancing Drug Therapies for an Increasing Case of a Parasitic infection Among Displaced Syrians
Cases of Cutaneous leishmaniasis (CL), a parasitic disease, has increased dramatically in Syria and neighboring countries as a result of the conflict-relat...
DEC 04, 2018
Drug Discovery
DEC 04, 2018
Drug Combination May Be Effective for Melanoma
Protein kinase inhibitors have been noted to be the most effective class of drugs in the treatment of melanoma—a deadly skin cancer of the melanocyte...
DEC 16, 2018
Health & Medicine
DEC 16, 2018
Important Biomedical Research At Risk Of Being Defunded
In September the Department of Health and Human Services (D.H.H.S.) released a statement citing “serious regulatory, moral and ethical considerations...
Loading Comments...